New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT02537418

First seen Apr 04, 2026 · Last updated Apr 30, 2026 · Updated 2 times

Summary

This study is for people with advanced solid tumors that cannot be cured. It tests two immunotherapy drugs, durvalumab and tremelimumab, given alone or with standard chemotherapy. The main goal is to find safe doses and see how well the drugs shrink or control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, H2L 4M1, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, K7L 5P9, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.